Patents by Inventor Neil Bifulco

Neil Bifulco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of protein kinase A
    Patent number: 12583856
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: March 24, 2026
    Assignee: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • STAT6 MODULATORS AND USES THEREOF
    Publication number: 20260015373
    Abstract: The present disclosure relates generally to STAT6 modulators and uses thereof, and more specifically to compounds, salts, and compositions thereof useful for treating conditions associated with STAT6.
    Type: Application
    Filed: July 11, 2025
    Publication date: January 15, 2026
    Inventors: Howard BREGMAN, John YEOMAN, Jennifer DOWNING, Samuel K. REZNIK, Ernest Allen SICKMIER, Giovanni CIANCHETTA, Rishi G. VASWANI, Neil BIFULCO, Xia TIAN, Andrew TASKER, Brian HODOUS
  • STAT MODULATORS AND USES THEREOF
    Publication number: 20250215030
    Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
    Type: Application
    Filed: March 30, 2023
    Publication date: July 3, 2025
    Inventors: Neil Bifulco, Howard Bregman, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Yong Tang, Andrew Tasker, Rishi G. Vaswani, Ernest Allen Sickmier, John Yeoman, Xia Tian
  • STAT MODULATORS AND USES THEREOF
    Publication number: 20250215029
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
    Type: Application
    Filed: January 10, 2023
    Publication date: July 3, 2025
    Inventors: Howard Bregman, Neil Bifulco, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Ernest Allen Sickmier, Yong Tang, Andrew Tasker, Xia Tian, Rishi G. Vaswani, John Yeoman
  • 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS
    Publication number: 20250179103
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditions. Preferred compounds are 6-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4H-pyrrolo[2,1-d][1,5]thiazocine derivatives.
    Type: Application
    Filed: February 27, 2023
    Publication date: June 5, 2025
    Inventors: Neil Bifulco, Howard Bregman, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Yong Tang, Andrew Tasker, Rishi G. Vaswani, Ernest Allen Sickmier, John Yeoman, Xia Tian
  • INHIBITORS OF PROTEIN KINASE A
    Publication number: 20240132490
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11059827
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 13, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK
    Publication number: 20190382410
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 19, 2019
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • ?-lactamase inhibitor compounds
    Patent number: 9623014
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20160175290
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • Beta-lactamase inhibitor compounds
    Patent number: 9309245
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 12, 2016
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • Beta-Lactamase Inhibitor Compounds
    Publication number: 20150073011
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Applicant: ASTRAZENECA AB
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • Heterocyclic urea derivatives and methods of use thereof
    Patent number: 8569484
    Abstract: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: October 29, 2013
    Assignee: Astrazeneca AB
    Inventors: Neil Bifulco, Allison Laura Choy, Olga Quiroga, Brian Alan Sherer
  • HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20120122817
    Abstract: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: May 28, 2010
    Publication date: May 17, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Neil Bifulco, Allison Laura Choy, Olga Quiroga, Brian Alan Sherer
  • Thiazole And Oxazole Kinase Inhibitors
    Publication number: 20110190280
    Abstract: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Application
    Filed: August 27, 2008
    Publication date: August 4, 2011
    Inventors: George Adjabeng, Neil Bifulco, Ronda G. Davis-Ward, Scott Howard Dickerson, Kelly Horne Donaldson, Philip Anthony Harris, Keith Hornberger, Kimberly Petrov, Tara Renae Rheault, Gregory Schaaf, John Stellwagen, David Edward Uehling, Alex Gregory Waterson
  • Thiazole And Oxazole Kinase Inhibitors
    Publication number: 20110098296
    Abstract: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Application
    Filed: December 4, 2008
    Publication date: April 28, 2011
    Inventors: George Adjabeng, Neil Bifulco, Ronda G. Davis-Ward, Scott Howard Dickerson, Keith Hornberger, Kimberly Petrov, Tara Renae Rheault, Daivd Edward Uehling, Alex Gregory Waterson
  • CCR5 antagonists as therapeutic agents
    Patent number: 7645771
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
  • Ccr5 antagonists as therapeutic agents
    Publication number: 20060229336
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Application
    Filed: December 12, 2003
    Publication date: October 12, 2006
    Inventors: Wieslaw Kazmierski, Chrisopher Aquino, Neil Bifulco, Eric Boros, Brian Chauder, Pek Chong, Maosheng Duan, Felix Deanda, Cecilia Koble, Ed Mclean, Jennifer Peckham, Angilique Perkins, James Thompson, Dana Vanderwall
  • Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
    Publication number: 20040180891
    Abstract: This invention relates to pyrazole derivatives of 1
    Type: Application
    Filed: March 15, 2004
    Publication date: September 16, 2004
    Inventors: Uday Khire, Chengzhi Zhang, Harold C E Kluender, Ingo Mugge, Zhengqui Hong, Jianxing Shao, Neil Bifulco, Pamela A Trail, Jacques Dumas, Rico C Lavoie, Xaio-Gao Liu, Veena Agarwal, Sharad K Verma, Lei Wang